Rgenix grabs $40 mln Series C
New York City-based Rgenix, Inc, a developer of first-in-class small molecule and antibody cancer therapeutics, has raised $40 million in Series C financing. Lepu Medical led the round with participation from other investors that included Oceanpine Capital, WuXi AppTec’s Corporate Venture Fund, Novo Holdings A/S, Sofinnova Partners, Alexandria Venture Investments LLC and the Partnership Fund for New York City’s Innovate NY Fund.
9 October 2018•1 min read
